Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
A retrospective analysis of 41 MS patients with uveitis compared to 123 MS controls found that disability accumulation (time to reach EDSS 3) occurred faster in patients with concurrent uveitis. The findings suggest that uveitis may be associated with worse MS disease progression.
A descriptive study of 170 MS patients across Morocco found female predominance, relapsing-remitting MS as the most common type, and common symptoms including fatigue, cognitive issues, and spasticity. Disease-modifying therapies (interferon beta-1a, azathioprine) were used alongside traditional/complementary medicine (cupping, Quranic recitation, apitherapy), with professional activity, treatment satisfaction, and stress significantly associated with relapse frequency.
This review examines recent neuroimaging technologies including MRI, PET, ocular imaging, and machine learning supported by MS research initiatives to better detect early MS pathology and monitor treatment response. The authors emphasize that while these biomarkers show promise for predicting and monitoring disease progression and may serve as clinical trial endpoints, longitudinal studies are needed to translate these measures into routine clinical practice.
A 33-year-old woman with relapsing-remitting MS treated with fingolimod for 5 years developed a solitary skin lesion that proved to be cryptococcal infection on biopsy, likely due to severe lymphocyte suppression from the immunosuppressive therapy. The case highlights the importance of thorough investigation of persistent skin lesions in MS patients on fingolimod, as only 6 such cutaneous cryptococcal infections have been previously reported in the literature.
This Cochrane review evaluates the efficacy and safety of alemtuzumab, a humanized monoclonal antibody, for treating various forms of multiple sclerosis compared to placebo or other active treatments. Primary outcomes include relapse-free survival, sustained disease progression, and adverse events, with secondary measures encompassing disability progression, quality of life, and MRI-detected lesions.